Increased propensity for calcium phosphate kidney stones with topiramate use

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Topiramate (TPM) is a neuromodulatory agent that was initially approved as an antiepileptic drug and is increasingly used in the treatment of a number of neurological and metabolic disorders. Among its various pharmacological actions, TPM has been shown to inhibit the activity of specific carbonic anhydrase enzymes in the kidney. This action is associated with the development of metabolic acidosis, hypocitraturia, hypercalciuria and elevated urine pH, leading to an increased risk of kidney stone disease. Despite the cautionary note in the package insert of TPM, the extent of these complications has not been fully explored. Few prescribing physicians are aware of these complications, underscoring the need for improved surveillance. Because the drug is among the most frequently prescribed agents in the US, more controlled studies are required to determine the prevalence of kidney stone disease among TPM users, and the optimal approach to prevent and treat nephrolithiasis in these individuals.

Original languageEnglish (US)
Pages (from-to)547-557
Number of pages11
JournalExpert Opinion on Drug Safety
Volume6
Issue number5
DOIs
StatePublished - Sep 2007

Fingerprint

Kidney Calculi
Kidney Diseases
Product Labeling
Hypercalciuria
Nephrolithiasis
Carbonic Anhydrases
Acidosis
Nervous System Diseases
Anticonvulsants
Urine
Pharmacology
Physicians
Kidney
calcium phosphate
topiramate
Enzymes
Pharmaceutical Preparations
Therapeutics

Keywords

  • Alkaline urine pH
  • Calcium phosphate stones
  • Metabolic acidosis
  • Topiramate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Increased propensity for calcium phosphate kidney stones with topiramate use. / Vega, Damaris; Maalouf, Naim M.; Sakhaee, Khashayar.

In: Expert Opinion on Drug Safety, Vol. 6, No. 5, 09.2007, p. 547-557.

Research output: Contribution to journalArticle

@article{f81903c3d06940628746cf911255dbe5,
title = "Increased propensity for calcium phosphate kidney stones with topiramate use",
abstract = "Topiramate (TPM) is a neuromodulatory agent that was initially approved as an antiepileptic drug and is increasingly used in the treatment of a number of neurological and metabolic disorders. Among its various pharmacological actions, TPM has been shown to inhibit the activity of specific carbonic anhydrase enzymes in the kidney. This action is associated with the development of metabolic acidosis, hypocitraturia, hypercalciuria and elevated urine pH, leading to an increased risk of kidney stone disease. Despite the cautionary note in the package insert of TPM, the extent of these complications has not been fully explored. Few prescribing physicians are aware of these complications, underscoring the need for improved surveillance. Because the drug is among the most frequently prescribed agents in the US, more controlled studies are required to determine the prevalence of kidney stone disease among TPM users, and the optimal approach to prevent and treat nephrolithiasis in these individuals.",
keywords = "Alkaline urine pH, Calcium phosphate stones, Metabolic acidosis, Topiramate",
author = "Damaris Vega and Maalouf, {Naim M.} and Khashayar Sakhaee",
year = "2007",
month = "9",
doi = "10.1517/14740338.6.5.547",
language = "English (US)",
volume = "6",
pages = "547--557",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Increased propensity for calcium phosphate kidney stones with topiramate use

AU - Vega, Damaris

AU - Maalouf, Naim M.

AU - Sakhaee, Khashayar

PY - 2007/9

Y1 - 2007/9

N2 - Topiramate (TPM) is a neuromodulatory agent that was initially approved as an antiepileptic drug and is increasingly used in the treatment of a number of neurological and metabolic disorders. Among its various pharmacological actions, TPM has been shown to inhibit the activity of specific carbonic anhydrase enzymes in the kidney. This action is associated with the development of metabolic acidosis, hypocitraturia, hypercalciuria and elevated urine pH, leading to an increased risk of kidney stone disease. Despite the cautionary note in the package insert of TPM, the extent of these complications has not been fully explored. Few prescribing physicians are aware of these complications, underscoring the need for improved surveillance. Because the drug is among the most frequently prescribed agents in the US, more controlled studies are required to determine the prevalence of kidney stone disease among TPM users, and the optimal approach to prevent and treat nephrolithiasis in these individuals.

AB - Topiramate (TPM) is a neuromodulatory agent that was initially approved as an antiepileptic drug and is increasingly used in the treatment of a number of neurological and metabolic disorders. Among its various pharmacological actions, TPM has been shown to inhibit the activity of specific carbonic anhydrase enzymes in the kidney. This action is associated with the development of metabolic acidosis, hypocitraturia, hypercalciuria and elevated urine pH, leading to an increased risk of kidney stone disease. Despite the cautionary note in the package insert of TPM, the extent of these complications has not been fully explored. Few prescribing physicians are aware of these complications, underscoring the need for improved surveillance. Because the drug is among the most frequently prescribed agents in the US, more controlled studies are required to determine the prevalence of kidney stone disease among TPM users, and the optimal approach to prevent and treat nephrolithiasis in these individuals.

KW - Alkaline urine pH

KW - Calcium phosphate stones

KW - Metabolic acidosis

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=35348972090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348972090&partnerID=8YFLogxK

U2 - 10.1517/14740338.6.5.547

DO - 10.1517/14740338.6.5.547

M3 - Article

C2 - 17877442

AN - SCOPUS:35348972090

VL - 6

SP - 547

EP - 557

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -